%0 Journal Article
%T Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129
%A Aleksandra Jankovic
%A Alfonso Buil
%A Amela Jusic
%A Andrejaana Andova
%A Andrew Baker
%A Angela Xuereb
%A Bence ¨¢gg
%A Branko Bugarski
%A Christos Papaneophytou
%A Clarissa Pedrosa da Costa Gomes
%A Costanza Emanueli
%A David de Gonzalo-Calvo
%A Dimitris Beis
%A Dimitris Kardassis
%A Emma Robinson
%A Fabio Martelli
%A Fay Betsou
%A Florence Pinet
%A Francisco J. Enguita
%A Gabriela M. Kuster
%A Gianluigi Condorelli
%A Gustavo Jos¨¦ Justo da Silva
%A Ines Poto£¿njak
%A Jan Hellemans
%A Kanita Karaduzovic-Hadziabdic
%A Kyriacos Felekkis
%A Lars Maegdefessel
%A Manlio Vinciguerra
%A Maria Carmo-Fonseca
%A Mariann Gy£¿ngy£¿si
%A Markus Scholz
%A Mark¨¦ta Hlavackova
%A Matthias Hackl
%A Maya Simionescu
%A Mehmet Birhan Yilmaz
%A Mitja Lustrek
%A Monika Bartekov¨¢
%A Monika Stoll
%A Morten Andre Hoydal
%A Octavian Popescu
%A Peter Ferdinandy
%A Przemyslaw Leszek
%A P£¿ivi Lakkisto
%A Risto Kerkel£¿
%A Sabrina Danilin
%A Serdal Arslan
%A Shlomo Sasson
%A Stephane Heymans
%A Stephanie Bezzina Wettinger
%A Susana Novella
%A Thierry Pedrazzini
%A Timothy O¡¯Brien
%A Yvan Devaux
%A Zoltan V. Varga
%J Archive of "Non-Coding RNA".
%D 2019
%R 10.3390/ncrna5020031
%X Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field. COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu)
%K cardiovascular disease
%K transcriptomics
%K best practices and guidelines
%K translational research
%K personalized medicine
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630366/